1Q Health Group

Following the acquisition of ABJ alive GmbH in 2024, NORD Holding continues its investment strategy in the CDMO sector for nutraceutical supplements and pharmaceuticals and acquires HKS health solutions (“HKS”) with two production sites in Germany (DRONANIA pharmaceuticals GmbH, Bad-Wörishofen) and Austria (HKS GmbH, Lengau). Both companies become the first members of the newly founded 1Q Health Group, thus laying the foundation for European expansion and a targeted extension of the product and service range in the field of contract manufacturing for high-quality nutraceutical supplements and pharmaceuticals. The founders of HKS - Benjamin Hawlik, Markus Koisser and Dirk Sachon - remain on the management board and reinvested to actively support the strategic development of the group.

With this acquisition, the 1Q Health Group establishes itself as one of the leading nutraceutical supplement and pharmaceutical CDMOs in the DACH region with around 250 employees at three state-of-the-art production sites in Germany and Austria. The portfolio offers customers a wide range of liquid and solid dosage forms, produced under GMP and IFS/FSSC conditions, as well as the option to between choose private label and white label products.

“With 1Q Health Group, we are pursuing a European buy-and-build strategy in the fast-growing market for high-quality nutraceutical supplements and pharmaceuticals. The acquisition of HKS fits perfectly with the ambition of a fully integrated CDMO with strong development expertise and abroad product portfolio at the highest quality level. We have followed the impressive development of HKS over the last few years and are now very much looking forward to working together,” says David Wössner, Director of NORDHolding.

“With the acquisition of HKS, we are setting an important milestone in our strategy to establish the 1Q Health Group as the leading full-service CDMO in Europe. Our customers gain a reliable partner, not only for the manufacturing of their products, but throughout the entire product life cycle. For us, this primarily includes the highest quality, delivery performance and flexibility in order to be able to serve both start-ups and corporations on the international market,” explains Philipp Ziehr, CEO of 1Q Health Group.

Dirk Sachon, co-founder of HKS, comments: “We are convinced that in 1Q Health Group we have found a strong and visionary partner who shares our values and quality standards. This partnership gives us the opportunity to further develop our company strategically, and at the same time create the basis for successful European expansion. Together we can optimally bundle our competencies to meet the growing requirements of our customers.”

The investment has been supported by the NORD Holding Healthcare team since February 2024 and underlines its expertise in the CDMO and VMS/ pharmaceutical outsourcing segment. On the part of NORD Holding, the transaction was implemented by André Seidel, David Wössner, Moritz Stolp and Kim Steinbart.

‍

About 1Q Health Group

1Q Health Group is a leading European nutraceutical supplement and pharmaceutical CDMO and development partner with around 250 employees, operating under the claim “FAST TRACK TO QUALITY”. As a one-stop-shop provider, the company's focus is on supporting dynamic customers throughout the entire product life cycle and beyond, from development and production to logistics and regulatory support. Hard capsules, liquids, powders and tablets are produced under GMP and IFS/FSSC conditions at three state-of-the-art production sites in Germany and Austria. In addition, 1Q Health supports customers with their international marketing and online presence.

Further information can be found at: www.1qhealth.com

‍

About HKS health solutions

HKS health solutions was created in 2021 through the merger of three specialized companies with comprehensive expertise along the entire value chain - from product development and contract manufacturing to warehousing and logistics. HKS is active in three core areas: contract manufacturing of high-quality nutraceutical supplements and medicinal products, the trade of over 1,500 raw materials (especially medicinal mushrooms), and the sale of private label products under the HAWLIK brand. With this broad positioning, the company serves customers of all sizes and requirements. The product focus is on the production of hard capsules, liquids, powders and tablets at the two production sites in Germany (DRONANIA pharmaceuticals GmbH, Bad-Wörishofen) and Austria (HKS GmbH, Lengau).

Further information canbe found at: www.hks-health-solutions.com